Health ❯ Medicine ❯ Pharmaceuticals

Drug Development

Clinical Trials Obesity Treatments Alzheimer's Disease Weight Loss Drugs Inflammatory Bowel Disease Obesity Treatment Weight Loss Treatments Pain Medication Muscle-Activating Compounds ERR Protein Activation Semaglutide Research and Development Amylyx Pharmaceuticals Drug Withdrawal Regulatory Updates Regulatory Approval Chemotherapeutic Drugs Gepotidacin Synthetic Biology Sildenafil Gleevec Synthesis Methods Malaria Treatment Sarepta Therapeutics COPD Treatment Quantum Computing in Medicine Experimental Drugs Leucovorin Bradykinin B2 Receptor Antagonists Synthetic Proteins Oncology Weight Loss Medications Epilepsy Treatment Cholesterol Medications Cancer Therapies Novo Nordisk Cholesterol Management Psoriasis Treatment Donidalorsen Acoziborole Winthrop Existing Drugs FDA Approval Cancer Treatments

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

The webcast will deliver the first Phase 3 readout for azetukalner in focal onset seizures.

EMA Backs Single-Dose Acoziborole for Gambiense Sleeping Sickness Outside EU

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Pfizer’s Monthly Obesity Shot Shows Mid-Stage Gains With Up to 12.3% Weight Loss

Lilly and Nimbus Strike Multi-Year AI Deal for Oral Obesity Drugs

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

Pharvaris’ Oral HAE Drug Deucrictibant Delivers Rapid Relief in Pivotal Phase 3

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Novartis Ianalumab Meets Efficacy and Safety Goals in Phase 3 Sjögren’s Trials

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

Artificial Enzymes Designed by Computers Rival Natural Catalysts

AI-Designed Rentosertib Improves Lung Function in Phase IIa IPF Trial